

Safety Notice

Medical Devices

Philips Ventilators

Trilogy 100, Trilogy 200, Garbin Plus, Aeris, LifeVent, A-Series BiPAP Hybrid A30, A-Series BiPAP V30 Auto, A-Series BiPAP A40, A-Series BiPAP A30



Philips Sleep and Respiratory care devices

E30

DreamStation ASV DreamStation ST, AVAPS

SystemOne ASV4

C-Series ASV

C-Series S/T and AVAPS

OmniLab Advanced+

SystemOne (Q-Series)

DreamStation

DreamStation Go

Dorma 400

Dorma 500

REMstar SE Auto



Priority 1 – For Immediate Action

HPRA Safety Notice: SN2021(05 Version 3) Update Issued: 31st March 2022

MANUFACTURER / SUPPLIER	HPRA CASE REFERENCE
Philips Respironics	V46723

SUR-F0017-5 1/4

ISSUE

The Health Products Regulatory Authority (HPRA) is issuing this Safety Notice to raise awareness of two issues identified with certain Philips Respironics ventilators, sleep and respiratory care devices (also known as 'CPAPs' or 'BiPAPs') manufactured before 26th April 2021.

Philips has advised that the two issues are due to the potential that polyester-based polyurethane (PE-PUR) sound abatement foam used in these devices:

- 1) may degrade into particles which may enter the device's air pathway and be ingested or inhaled by the user and,
- 2) may emit certain chemicals.

A list of all affected models and further information on the issues is available in the accompanying field safety notices (FSNs) issued by Philips. Where certain device models may have been previously marketed under alternate names (eg. SystemOne REMstar) please contact Philips or your provider to establish if your device is within the scope of this issue. It is important to note that the FSNs advise not stopping or changing your prescribed therapy without first consulting your doctor.

ACTION OR RECOMMENDATIONS

The HPRA advises users to:

1. Identify whether your device is one of the impacted models listed in the accompanying FSNs.

Based on the current information supplied by Philips, the Health Service Executive (HSE) recommends that all patients and device users continue to use their device as prescribed until a replacement device is supplied or the device repaired. Further details are available on the HSE website

https://www.hse.ie/eng/services/news/newsfeatures/advice-philips-respironics-devices/

- Register your device at <u>https://www.philips.ie/healthcare/e/sleep/communications/src-update</u>
 Call 1800 851 241 if you cannot visit the website or do not have internet access.
- 3. Report any adverse incidents associated with these devices to the manufacturer and to the HPRA.

The HPRA advises that healthcare professionals:

- 1. Refer to the accompanying FSNs for further information in relation to this issue.
- 2. Acknowledge receipt of the FSNs if you have not already done so.
- 3. Refer to information provided by Philips for physicians and other medical care providers at https://www.philips.ie/healthcare/e/sleep/communications/src-update/information-for-physicians-and-providers
- 4. Report any adverse incidents associated with this device to the manufacturer and to the HPRA.

SUR-F0017-5 2/4

Note – This is an emerging issue, the HPRA is working with the HSE, hospital and community services to further assess this issue and the potential impact on patients in Ireland. As information becomes available, the up to date HSE advice will be published on their website https://www.hse.ie/eng/services/news/newsfeatures/advice-philips-respironics-devices/

The HPRA has also published a Special Topics webpage for this issue at https://www.hpra.ie/homepage/medical-devices/special-topics/philips-sleep-and-respiratory-care-devices

Suppliers are requested to forward a copy of this Safety Notice and the accompanying FSNs to all affected users and to any organisation / persons to which / whom these devices have been transferred.

TARGET GROUPS

Users of affected devices and their carers

Respiratory consultants

General practitioners

Community care managers

Paediatricians Risk managers

Supplies managers

Outpatient clinics

Intensive Care Units

Neonatal Intensive Care Units

Nursing Homes Sleep Centres

Rehabilitation Units

BACKGROUND

Philips Respironics has initiated a global field safety corrective action and issued the accompanying FSNs to notify device users of the two issues outlined above. As described in these notices, the manufacturer has identified a number of potential risks, which may have significant effects on the users of these devices in the long term, including potential risks related to exposure to carcinogens.

To date, Philips has received several global complaints regarding the presence of black debris/particles within the air pathway circuit (extending from the device outlet, humidifier, tubing, and mask). Philips also has received reports of headache, upper airway irritation, cough, chest pressure and sinus infection.

Philips has advised that they are deploying a permanent corrective action to address these issues. Further information on this corrective action and the status of the field action are available at: https://www.philips.ie/healthcare/e/sleep/communications/src-update

MANUFACTURER / AUTHORISED REPRESENTATIVE / DISTRIBUTOR CONTACT INFORMATION

Enquiries to the **manufacturer** should be addressed to:

Philips Respironics Inc, Telephone: 1800851241

312 Alvin Drive, E-mail: devicevigilanceuki@philips.com

SUR-F0017-5 3/4

New Kensington, 15068, Website:

USA https://www.philips.ie/healthcare/e/sleep/communications/src-

update

Enquiries to the authorised representative should be addressed to:

Respironics Deutschland Telephone: 1800851241

GmbH & Co. KG, E-mail: devicevigilanceuki@philips.com

Gewerbestr 17.

Herrsching 82211, Germany

Enquiries to the **distributors** should be addressed to:

Air Liquide

18 H Rosemount Business Telephone: 1800 740202 (Option 3)
Park, Ballycoolin, Dublin 11 E-mail: healthie@airliquide.ie

Website: www.airliquide.ie

Direct Medical

Suite 2 Gateway Centre, Telephone: 09064 90190

Monksland, Athlone, Co. E-mail: patient.support@directmedical.ie

Roscommon, N37 CD77

Cardiac Services

Unit 3a, Northern Cross Telephone: (01) 8307499

Business Park, Finglas, E-mail: recalls@cardiac-services.com

Dublin 11, D11 WY11

BOC Healthcare

Bluebell, Dublin 12 Telephone: 1800 22 02 02

E-mail: healthcareinfo.ie@boc.com

PAP Healthcare

18 Laburnum Park, Telephone: (021) 419 3009 (Option 4)
Model Farm Road, Cork E-mail: support@paphealthcare.ie

Medicare Health & Living

Glencormack Business Park, Telephone: (01) 2014900 Kilmacanogue, E-mail: info@medicare.ie

Co. Wicklow, A98 P2R1

HPRA CONTACT INFORMATION

All adverse incidents relating to a medical device should be reported to:

Health Products Regulatory Authority

Telephone: +353-1-6764971

Kevin O'Malley House E-mail: devicesafety@hpra.ie

Earlsfort Centre Website: www.hpra.ie

Earlsfort Terrace

Dublin 2

SUR-F0017-5 4/4